| Status | Study |
| Enrolling by invitation |
Study Name: A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH) Condition: Achondroplasia Date: 2016-02-12 Interventions: Drug: BMN 111 BMN 111 will be administered daily for up to 260 weeks. |
| Enrolling by invitation |
Study Name: Achondroplasia Natural History Multicenter Clinical Study Condition: Achondroplasia Date: 2015-10-26 |
| Enrolling by invitation |
Study Name: A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia Condition: Achondroplasia Date: 2013-04-18 Interventions: Drug: BMN 111 BMN 111 will be administered daily for 24 months in an open-label sequential dose adjustme |
| Recruiting |
Study Name: A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients With Achondroplasia Condition: Achondroplasia Date: 2012-05-11 |
| Completed |
Study Name: A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers Condition: Achondroplasia Date: 2012-03-14 Interventions: Drug: BMN 111 SC injection, Pa |
| Completed |
Study Name: C-Type Natriuretic Peptide and Achondroplasia Condition: Achondroplasia Hypochondroplasia Date: 2012-02-13 |
| Completed |
Study Name: Special Survey for Long Term Application Condition: Genetic Disorder Achondroplasia Date: 2012-01-19 Interventions: Drug: somatropin Prescription of somatropin at the discretion of the physician |
| Completed |
Study Name: A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin Condition: Genetic Disorder Achondroplasia Date: 2011-09-14 Interventions: Drug: somatropin Dosage and administration to be prescribed by the physician as a result of a normal cli |
| Completed |
Study Name: Issues Surrounding Prenatal Genetic Testing for Achondroplasia Condition: Achondroplasia Dwarfism Date: 1999-11-03 |